Aosaikang's subsidiary Methotrexate Injection has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.
Aosaikang's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., recently obtained the Drug Registration Certificate for Methotrexate Injection approved by the National Medical Products Administration. This drug is a dihydrofolate reductase inhibitor with broad-spectrum antitumor activity, which can be used to treat breast cancer, gestational trophoblastic neoplasia, and other conditions, or in combination with other chemotherapy drugs to treat various cancers
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments